Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-G21: Pembrolizumab in Japanese Pediatric Solid Tumors/Lymphomas and Adult Merkel Cell Carcinoma
NCT07302347Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in solid tumor, lymphoma, Merkel cell carcinoma (MCC), melanoma, Hodgkin lymphoma (HL), sponsored by Merck & Co.. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
solid tumorlymphomaMerkel cell carcinoma (MCC)melanomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT07302347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302347.